PDF(Pubmed)
Abstract：
BACKGROUND: Hepatic encephalopathy (HE) is a major complication of acute liver failure, cirrhosis and transjugular intrahepatic portosystemic shunt (TIPS) placement. Its clinical manifestations range from mild cognitive deficits to coma. Furthermore, HE is a financial burden to a patient\'s family and significantly affects the patient\'s quality of life. In clinical practice, proton pump inhibitors (PPIs) are widely used for the treatment of HE. The use of PPIs is associated with an increased risk of post-TIPS HE; however, findings on the risk relationship between PPIs and post-TIPS HE are inconsistent. Therefore, a systematic evaluation of the relationship is needed to further provide valid evidence for the rational use of PPIs in patients who undergo TIPS.
METHODS: PubMed, Web of Science, Cochrane Library and Embase will be searched extensively for relevant information. Information from 1 July 2023 to 31 July 2023 in these databases will be included. Primary outcomes will be the use of PPIs and incidence of HE after TIPS; secondary outcomes will be survival, dose dependence and adverse events. This meta-analysis will be reported in accordance with the 50 Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020. The risk of bias, heterogeneity and quality of evidence of the included studies will be evaluated prior to the data analysis. All data will be analysed using Review Manager (V.5.4.1) and Stata (V.17.0) statistical software.
BACKGROUND: Ethical approval will not be necessary for this review and meta-analysis. The results of the study will be published in a peer-reviewed journal.
UNASSIGNED: CRD42022359208.
METHODS: PubMed, Web of Science, Cochrane Library and Embase will be searched extensively for relevant information. Information from 1 July 2023 to 31 July 2023 in these databases will be included. Primary outcomes will be the use of PPIs and incidence of HE after TIPS; secondary outcomes will be survival, dose dependence and adverse events. This meta-analysis will be reported in accordance with the 50 Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020. The risk of bias, heterogeneity and quality of evidence of the included studies will be evaluated prior to the data analysis. All data will be analysed using Review Manager (V.5.4.1) and Stata (V.17.0) statistical software.
BACKGROUND: Ethical approval will not be necessary for this review and meta-analysis. The results of the study will be published in a peer-reviewed journal.
UNASSIGNED: CRD42022359208.
摘要：
背景：肝性脑病（HE）是急性肝衰竭的主要并发症，肝硬化和经颈静脉肝内门体分流术（TIPS）放置。其临床表现范围从轻度认知障碍到昏迷。此外，HE是患者家庭的经济负担，并显著影响患者的生活质量。在临床实践中,质子泵抑制剂(PPIs)广泛用于HE的治疗。PPI的使用与TIPSHE后的风险增加相关；然而，关于PPI和TIPS后HE之间风险关系的结果不一致。因此,需要对两者的关系进行系统评估,以便进一步为接受TIPS治疗的患者合理使用PPI提供有效证据.
方法：PubMed，WebofScience,将广泛搜索Cochrane图书馆和Embase以获取相关信息。这些数据库中的2023年7月1日至2023年7月31日的信息将包括在内。主要结果将是PPI的使用和TIPS后HE的发生率；次要结果将是生存率，剂量依赖性和不良事件。该荟萃分析将根据2020年系统评论和荟萃分析的50个首选报告项目进行报告。偏见的风险，纳入研究的异质性和证据质量将在数据分析前进行评估.所有数据将使用ReviewManager(V.5.4.1)和Stata(V.17.0)统计软件进行分析。
背景：本综述和荟萃分析不需要道德批准。研究结果将发表在同行评审的期刊上。
■CRD42022359208。
方法：PubMed，WebofScience,将广泛搜索Cochrane图书馆和Embase以获取相关信息。这些数据库中的2023年7月1日至2023年7月31日的信息将包括在内。主要结果将是PPI的使用和TIPS后HE的发生率；次要结果将是生存率，剂量依赖性和不良事件。该荟萃分析将根据2020年系统评论和荟萃分析的50个首选报告项目进行报告。偏见的风险，纳入研究的异质性和证据质量将在数据分析前进行评估.所有数据将使用ReviewManager(V.5.4.1)和Stata(V.17.0)统计软件进行分析。
背景：本综述和荟萃分析不需要道德批准。研究结果将发表在同行评审的期刊上。
■CRD42022359208。
